GlassScriptPhysician profile
Ryan K Biga
NPI 1134486822
$5,309.70
in general payments reported to CMS, 2019-2025
49 companies · $944 in 2025
The $944 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $333 · 2021: $570 · 2022: $816 · 2023: $1,032 · 2024: $904 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,880.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $950.57 | 2019-2025 | Qulipta, Ubrelvy, Viberzi |
| Novo Nordisk INC | $764.04 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $581.39 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $425.23 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $290.78 | 2022-2025 | Rexulti |
| Amgen INC. | $250.81 | 2019-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $196.82 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $168.22 | 2019-2024 | Invega Sustenna, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.13 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $149.17 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $131.88 | 2020-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Medtronic, INC. | $98.22 | 2022-2025 | Symplicity G3, Venaseal |
| Takeda Pharmaceuticals U.S.A., INC. | $79.95 | 2019-2022 | |
| Astellas Pharma US INC | $77.05 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.74 | 2019-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Biga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.